Tags

Type your tag names separated by a space and hit enter

Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.

Abstract

Inactivating mutations of the CHEK2 and STK11 genes are responsible for Li-Fraumeni and Peutz-Jeghers syndrome, respectively, both autosomal dominant syndromes associated with an increased risk of breast cancer. The PALB2/FANCN gene encodes a nuclear partner of BRCA2 and acts as a linker between BRCA1 and BRCA2. Monoallelic PALB2 truncating mutations were shown to confer higher risk of breast cancer. To evaluate the proportion of French Canadian non-BRCA1/BRCA2 families with high risk of breast cancer potentially harboring alterations in these three breast cancer susceptibility genes, the whole coding and flanking intronic sequences were analyzed in a series of 96 high-risk breast cancer individuals. Despite no PALB2 deleterious truncating mutations being identified, the c.1100delC breast-cancer-associated CHEK2 mutation and a STK11 mutation reported to be the causative mutation in a Peutz-Jeghers family were identified. This extensive analysis also led to the identification of several variants in these genes. Ascertainment of allele frequency of these variants in a cohort of 96 healthy unrelated women suggests a difference in allele frequency for two STK11 intronic variants. In addition, large genomic rearrangements in both STK11 and PALB2 were also examined. Our analysis led to the conclusion that CHEK2, STK11, and PALB2 mutations or large genomic rearrangements of either STK11 or PALB2 are rare, and do not contribute to a substantial fraction of breast cancer susceptibility in high-risk French Canadian breast cancer families.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Cancer Genomics Laboratory, Department of Molecular Medicine, Laval University, Québec City, Québec, Canada.

    , , , , ,

    Source

    MeSH

    Adult
    Aged
    Breast Neoplasms
    Canada
    Carcinoma
    Checkpoint Kinase 2
    DNA Mutational Analysis
    Family
    Fanconi Anemia Complementation Group N Protein
    Female
    Genes, BRCA1
    Genes, BRCA2
    Genetic Predisposition to Disease
    Humans
    Middle Aged
    Nuclear Proteins
    Protein-Serine-Threonine Kinases
    Quebec
    Risk
    Tumor Suppressor Proteins

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    20722467

    Citation

    Guénard, Frédéric, et al. "Evaluation of the Contribution of the Three Breast Cancer Susceptibility Genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian Families With High Risk of Breast Cancer." Genetic Testing and Molecular Biomarkers, vol. 14, no. 4, 2010, pp. 515-26.
    Guénard F, Pedneault CS, Ouellette G, et al. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers. 2010;14(4):515-26.
    Guénard, F., Pedneault, C. S., Ouellette, G., Labrie, Y., Simard, J., & Durocher, F. (2010). Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genetic Testing and Molecular Biomarkers, 14(4), pp. 515-26. doi:10.1089/gtmb.2010.0027.
    Guénard F, et al. Evaluation of the Contribution of the Three Breast Cancer Susceptibility Genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian Families With High Risk of Breast Cancer. Genet Test Mol Biomarkers. 2010;14(4):515-26. PubMed PMID: 20722467.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. AU - Guénard,Frédéric, AU - Pedneault,Christopher St-Laurent, AU - Ouellette,Geneviève, AU - Labrie,Yvan, AU - Simard,Jacques, AU - ,, AU - Durocher,Francine, PY - 2010/8/21/entrez PY - 2010/8/21/pubmed PY - 2010/12/14/medline SP - 515 EP - 26 JF - Genetic testing and molecular biomarkers JO - Genet Test Mol Biomarkers VL - 14 IS - 4 N2 - Inactivating mutations of the CHEK2 and STK11 genes are responsible for Li-Fraumeni and Peutz-Jeghers syndrome, respectively, both autosomal dominant syndromes associated with an increased risk of breast cancer. The PALB2/FANCN gene encodes a nuclear partner of BRCA2 and acts as a linker between BRCA1 and BRCA2. Monoallelic PALB2 truncating mutations were shown to confer higher risk of breast cancer. To evaluate the proportion of French Canadian non-BRCA1/BRCA2 families with high risk of breast cancer potentially harboring alterations in these three breast cancer susceptibility genes, the whole coding and flanking intronic sequences were analyzed in a series of 96 high-risk breast cancer individuals. Despite no PALB2 deleterious truncating mutations being identified, the c.1100delC breast-cancer-associated CHEK2 mutation and a STK11 mutation reported to be the causative mutation in a Peutz-Jeghers family were identified. This extensive analysis also led to the identification of several variants in these genes. Ascertainment of allele frequency of these variants in a cohort of 96 healthy unrelated women suggests a difference in allele frequency for two STK11 intronic variants. In addition, large genomic rearrangements in both STK11 and PALB2 were also examined. Our analysis led to the conclusion that CHEK2, STK11, and PALB2 mutations or large genomic rearrangements of either STK11 or PALB2 are rare, and do not contribute to a substantial fraction of breast cancer susceptibility in high-risk French Canadian breast cancer families. SN - 1945-0257 UR - https://www.unboundmedicine.com/medline/citation/20722467/Evaluation_of_the_contribution_of_the_three_breast_cancer_susceptibility_genes_CHEK2_STK11_and_PALB2_in_non_BRCA1/2_French_Canadian_families_with_high_risk_of_breast_cancer_ L2 - https://www.liebertpub.com/doi/full/10.1089/gtmb.2010.0027?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -